help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-0594
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meigs, J. B.
Right arrow Articles by D’Agostino, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meigs, J. B.
Right arrow Articles by D’Agostino, R. B.
Related Collections
Right arrow Cardiovascular Endocrinology
Right arrow Diabetes and Insulin
Right arrow Obesity
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 8 2906-2912
Copyright © 2006 by The Endocrine Society

Body Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease

James B. Meigs, Peter W. F. Wilson, Caroline S. Fox, Ramachandran S. Vasan, David M. Nathan, Lisa M. Sullivan and Ralph B. D’Agostino

General Medicine Division and Department of Medicine (J.B.M.) and Diabetes Unit and Department of Medicine (D.M.N.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; Department of Endocrinology, Diabetes, and Medical Genetics (P.W.F.W.), Medical University of South Carolina, Charleston, South Carolina 29403; The National Heart, Lung, and Blood Institute’s Framingham Heart Study and the Division of Endocrinology, Diabetes, and Hypertension (C.S.F.), Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115; The National Heart, Lung, and Blood Institute’s Framingham Heart Study and the Evans Department of Medicine, Whitaker Cardiovascular Institute, and Preventive Medicine Section (R.S.V.), Boston University School of Medicine, Boston, Massachusetts 02215; and Department of Mathematics, Statistics, and Consulting Unit (L.M.S., R.B.D.), Boston University, Boston, Massachusetts 02118

Address all correspondence and requests for reprints to: James B. Meigs, M.D., M.P.H., General Medicine Division, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, Massachusetts 02114. E-mail: jmeigs{at}partners.org.

Context: Metabolic risk conferred by adiposity may be due to associated risk factor clustering.

Objective: The objective of this study was to assess risk for diabetes or cardiovascular disease (CVD) stratified by body mass index (BMI) and the presence or absence of metabolic syndrome (MetS) or insulin resistance (IR).

Design, Setting, and Participants: This was a community-based, longitudinal study of 2902 people (55% women, mean age 53 yr) without diabetes or CVD in 1989–1992 followed for up to 11 yr. We categorized subjects by normal weight (BMI < 25 kg/m2), overweight (25–29.9 kg/m2), or obese (>30 kg/m2) and by the National Cholesterol Education Program’s Adult Treatment Panel MetS or the top quartile of homeostasis model IR. We used proportional hazard models to estimate risk relative to normal weight and no MetS or IR.

Main Outcome Measure: Incident type 2 diabetes (treatment or fasting glucose ≥ 7 mmol/liter, 141 events) or CVD (myocardial infarction, stroke, or claudication, 252 events) were measured.

Results: Among 1056 normal-weight subjects, 7% had MetS and a risk factor-adjusted relative risk for diabetes of 3.97 (95% confidence interval, 1.35–11.6) and for CVD of 3.01 (1.68–5.41). Among 638 obese subjects, 37% did not have MetS or significantly increased risk. Obese subjects with MetS had an adjusted relative risk for diabetes of 10.3 (5.44–19.5) and for CVD of 2.13 (1.43–3.18). Results were similar in analyses of BMI-IR categories.

Conclusions: People with normal weight and MetS or IR or with obesity but no MetS or IR were not uncommon in our sample. Risk factor clustering or IR appear to confer much of the risk for diabetes or CVD commonly associated with elevated BMI.




This article has been cited by other articles:


Home page
 CirculationHome page
J. Arnlov, E. Ingelsson, J. Sundstrom, and L. Lind
Impact of Body Mass Index and the Metabolic Syndrome on the Risk of Cardiovascular Disease and Death in Middle-Aged Men
Circulation, January 19, 2010; 121(2): 230 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
B. Longo-Mbenza, J. Kasiam Lasi On'kin, A. Nge Okwe, N. Kangola Kabangu, and S. Mbungu Fuele
Metabolic syndrome, aging, physical inactivity, and incidence of type 2 diabetes in general African population
Diabetes and Vascular Disease Research, January 1, 2010; 7(1): 28 - 39.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
K. Nakajima and M. Saito
Lower Vital Capacity Is Associated With Diabetes but Not With Metabolic Syndrome in Nonobese Japanese Men: Response to Oda and Kawai
Diabetes Care, November 1, 2009; 32(11): e135 - e135.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J.-L. Chiasson
Early Insulin Use in Type 2 Diabetes: What are the cons?
Diabetes Care, November 1, 2009; 32(suppl_2): S270 - S274.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Meigs
Multiple Biomarker Prediction of Type 2 Diabetes
Diabetes Care, July 1, 2009; 32(7): 1346 - 1348.
[Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev., December 1, 2008; 29(7): 777 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. L. Rosenzweig, E. Ferrannini, S. M. Grundy, S. M. Haffner, R. J. Heine, E. S. Horton, and R. Kawamori
Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3671 - 3689.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. Chinali, G. de Simone, M. J. Roman, L. G. Best, E. T. Lee, M. Russell, B. V. Howard, and R. B. Devereux
Cardiac Markers of Pre-Clinical Disease in Adolescents With the Metabolic Syndrome: The Strong Heart Study
J. Am. Coll. Cardiol., September 9, 2008; 52(11): 932 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. S. Ford, C. Li, and N. Sattar
Metabolic Syndrome and Incident Diabetes: Current state of the evidence
Diabetes Care, September 1, 2008; 31(9): 1898 - 1904.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
A. M. Wassink, Y. Van Der Graaf, S. S Soedamah-Muthu, W. Spiering, and F. L. Visseren
Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease
Diabetes and Vascular Disease Research, June 1, 2008; 5(2): 114 - 122.
[Abstract] [PDF]

Home page
 Eur J EndocrinolHome page
S Cupisti, N Kajaia, R Dittrich, H Duezenli, M W Beckmann, and A Mueller
Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome
Eur. J. Endocrinol., May 1, 2008; 158(5): 711 - 719.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Sorisky MD
A new predictor for type 2 diabetes?
Can. Med. Assoc. J., January 29, 2008; 178(3): 313 - 315.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Meigs, M. G. Larson, C. S. Fox, J. F. Keaney Jr., R. S. Vasan, and E. J. Benjamin
Association of Oxidative Stress, Insulin Resistance, and Diabetes Risk Phenotypes: The Framingham Offspring Study
Diabetes Care, October 1, 2007; 30(10): 2529 - 2535.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
C. Lorenzo, M. Serrano-Rios, M. T. Martinez-Larrad, C. Gonzalez-Villalpando, J. L. Gonzalez-Sanchez, M. J. Martinez-Calatrava, R. Gabriel, and S. M. Haffner
Is Waist Circumference an Essential Component of the Metabolic Syndrome?
Diabetes Care, August 1, 2007; 30(8): 2141 - 2142.
[Full Text] [PDF]

Home page
 J Gerontol A Biol Sci Med SciHome page
C. S. Blaum, N. A. West, and M. N. Haan
Is the Metabolic Syndrome, With or Without Diabetes, Associated With Progressive Disability in Older Mexican Americans?
J Gerontol A Biol Sci Med Sci, July 1, 2007; 62(7): 766 - 773.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
G. M. Reaven
The Individual Components of the Metabolic Syndrome: Is There a Raison d'Etre?
J. Am. Coll. Nutr., June 1, 2007; 26(3): 191 - 195.
[Full Text] [PDF]

Home page
 pdiHome page
A. G. Zenovich and D. A. Taylor
CELL THERAPY IN KIDNEY DISEASE: CAUTIOUS OPTIMISM... BUT OPTIMISM NONETHELESS
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S94 - S103.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Meigs, M. K. Rutter, L. M. Sullivan, C. S. Fox, R. B. D'Agostino Sr., and P. W.F. Wilson
Impact of Insulin Resistance on Risk of Type 2 Diabetes and Cardiovascular Disease in People With Metabolic Syndrome
Diabetes Care, May 1, 2007; 30(5): 1219 - 1225.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Sturmer, J. E. Buring, I-M. Lee, J. M. Gaziano, and R. J. Glynn
Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2391 - 2397.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society